Is Trastuzumab on the market?

Trastuzumab (Trastuzumab) is a monoclonal antibody used to treat breast and gastric cancer. It is sold under trade names such as Herceptin. It is specifically used for HER2 receptor-positive cancers. Trastuzumab can be used alone or together with other chemotherapy drugs, and is administered clinically by slow intravenous injection and subcutaneous injection.

Trastuzumab was approved for medical use in the United States in September 1998 by the U.S. Food and Drug Administration (FDA) and in the European Union in August 2000. In December 2017, the FDA approved OGIVRI (trastuzumab-dkst) as a biosimilar to trastuzumab for the treatment of patients with breast cancer or metastatic gastric cancer (gastric or gastroesophageal junction adenocarcinoma) whose tumors overexpress the HER2 gene (HER2+). Based on clinical data, it exhibits similar biological properties to Herceptin and is the first biosimilar approved in the United States for the treatment of breast or gastric cancer.

Trastuzumab is sold under the brand name Herceptin in China and has entered the scope of Class B medical insurance, but it may be limited to patients who meet the indications for this drug, such as patients with HER2-positive metastatic breast cancer and its adjuvant and neoadjuvant treatment or HER2-positive metastatic gastric cancer. The price is around 6,000 yuan. The original trastuzumab drug has also been launched overseas. The ingredients of domestic and foreign original drugs are basically the same. For specific prices and drug details, you can consult a medical consultant. Currently, there are no generic trastuzumab drugs on the market.